Table of contents | EMCDDA Report on the risk assessment of mephedrone

Main Menu

Psychopharmacology

59.4%		United States
8.7%		United Kingdom
5%		Canada
4%		Australia
3.5%		Philippines
2.6%		Netherlands
2.4%		India
1.6%		Germany
1%		France
0.7%		Poland

Today:	211
Yesterday:	251
This Week:	211
Last Week:	2221
This Month:	4799
Last Month:	6796
Total:	129398

Table of contents

Written by EMCDDA |

PDF

|

Print

|

E-mail

Reports - EMCDDA Report on the risk assessment of mephedrone

1. Introduction

2. Physical and chemical description of mephedrone and its mechanisms of action, including its medical value

3. Chemical precursors that are used for the manufacture of mephedrone

4. Health risks associated with mephedrone

5. Social risks associated with mephedrone

6. Information on the level of involvement of organised crime and information on seizures and/or detections by the authorities, and the manufacture of mephedrone

7. Information on any assessment of mephedrone in the United Nations system

8. Description of the control measures that are applicable to mephedrone in the Member States

9. Options for control and the possible consequences of the control measures

10. Conclusion

11. List of annexes

Next >

Show Other Articles Of This Author

Contents (31 May 2011)
Foreword (30 May 2011)
Introduction (29 May 2011)
Report on the risk assessment of ketamine in th... (28 May 2011)
1. Chemical description (27 May 2011)